Our retrospective clinical analyses suggest that HNSCC patients with elevated expression of CXCR2 and/or its ligands may particularly benefit — either from broad range SASP-targeting radio(chemo)therapy via interference with NF-κB function or more specifically from targeting distinct cytokine/receptor systems. The gene discussed is CXCR2; the disease is head and neck squamous cell carcinoma.